Robert F. Carey
Independent DirectorMr. Robert F. Carey, also known as Bob, serves as Director of Cour Pharmaceutical Development Company, Inc. since February 08, 2023 and serves as its Lead Independent Director. He Co-Founded ACELYRIN, Inc. and was its Secretary and Director. He had been the President of ACELYRIN, Inc. since July 2020 and served as its Chief Financial Officer until July 18, 2022. He served as Chief Operating Officer of ACELYRIN, Inc. He is an Independent Chairman of the Board at Beyond Air, Inc. since February 2026. He is an Independent Director at Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.) since February 13, 2019 and also was its Lead Independent Director. Mr. Carey serves as Independent Director at FS Development Corp. now known as Disc Medicine, Inc. since August 12, 2020 to February 2021. He served as Chief Business Officer and Executive Vice President of Horizon Therapeutics Public Limited Company (previously known as Horizon Pharma plc) since March 5, 2014 until October 1, 2019. Mr. Carey has an extensive experience in investment banking in the biotechnology, medical technology and life sciences industries. Prior to joining Horizon Therapeutics Public Limited Company in March 2014, he spent many years as Managing Director and Head of the Life Sciences Investment Banking Group at JMP Securities LLC from March 2003 to March 2014. He served as Co-Head of Healthcare Investment Banking at JMP Securities LLC. He served as a Managing Director and senior Member of the Healthcare Group at Dresdner Kleinwort Wasserstein and Managing Director and senior Member of the corporate finance team at Vector Securities International, Inc. He has assisted biotechnology, medical technology and life sciences companies in raising private placements, initial public offerings and follow-on offerings and has been a financial advisor on approximately 35 mergers, acquisitions and strategic alliances. Mr. Carey’s background also includes employment with Shearson Lehman Hutton in its Corporate Finance Group, Ernst & Whinney in its Corporate Audit Group and The Executive Office of the President, Office of Management and Budget. He also has held roles at Red Hen Bread. He has been an Independent Director of Sangamo Therapeutics, Inc. since June 14, 2016. Mr. Carey serves on the Board of Beyond Cancer Ltd. He served as a Director of Argos Therapeutics, Inc. since September 23, 2015 until November 30, 2018. He serves as a Director of Gimbal InStadium, Inc. (Formally known as InStadium, Inc). Mr. Carey received his BS in Accounting from the University of Notre Dame. Mr. Carey serves on the Board of Hawthorne Race Course, Incorporated. Mr. Carey serves as a Director at Beyond Cancer Ltd. Mr. Carey received his B.B.A. in Accounting from University of Notre Dame - Mendoza College of Business - Department of Accountancy from 1976 to 1981.
Positions
- Company NameSangamo Therapeutics, Inc.Stock CodeSGMOQPositionIndependent DirectorColleagues
- ADAlexander D. MacraeCEO, President & Director
- HSH. Stewart ParkerIndependent Chairwoman of the Board
- SBScott B. WilloughbySenior VP, Chief Legal Officer & Corporate Secretary
- NDNathalie Dubois-StringfellowSenior VP & Chief Development Officer
- NJNikunj JainInterim CFO and Principal Financial & Accounting Officer
- PRPhillip RamseyChief Technical Officer
- RFRobert F. CareyIndependent Director
- KLKaren L. SmithIndependent Director
- RDRoger D. KornbergMember of Scientific Advisory Board
- Company NameBeyond Air, Inc.Stock CodeXAIRPositionIndependent Chairman of the BoardColleagues
- RSRobert Scott GoodmanCEO & Director
- DJDaniel J. MoorheadChief Financial Officer
- MAMichael A. GaulChief Operating Officer
- DDDenton DrewellPrincipal Accounting Officer & Controller
- ARAndrew R. ColinSenior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board
- EJErick J. LuceraIndependent Director
- YLYoori LeeIndependent Director
